Skip to content

Efficacy and Survival of Locally Advanced Hypopharyngeal Cancer Patients Under Multidisciplinary Treatment Decisions with Neoadjuvant Therapy as an Organ Preservation Strategy: A Real-World Study

Efficacy and Survival of Locally Advanced Hypopharyngeal Cancer Patients Under Multidisciplinary Treatment Decisions with Neoadjuvant Therapy as an Organ Preservation Strategy: A Real-World Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114159
Enrollment
Unknown
Registered
2025-12-08
Start date
2024-10-14
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

locally advanced hypopharyngeal carcinoma

Interventions

A:Patients with CR or PR in the primary lesion and non-PD in lymph nodes after neoadjuvant therapy undergo radical radiotherapy.:none
C: Patients with a CR/PR in the primary lesion and non-PD in lymph nodes, SD/PD in the primary lesion and non-PD in lymph nodes, or any status in the primary lesion with PD in lymph nodes undergo surg
B: Patients with SD or PD in the primary lesion and non-PD in lymph nodes, or any status in the primary lesion with PD in lymph nodes, receive radical radiotherapy.:none

Sponsors

Beijing Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. From January 2017 to December 2024, the center diagnosed pathologically as locally advanced hypopharyngeal cancer, cT1N+M0/T2-4N any M0; 2. Age >= 18 years; 3. After multidisciplinary discussion on head and neck tumors, it was decided to adopt neoadjuvant therapy as an organ preservation strategy; 4. Clear treatment process and complete documentation, and willing to accept follow-up.

Exclusion criteria

Exclusion criteria: 1. Combined with secondary tumor; 2. No discussion with MDT; 3. Data not complete.

Design outcomes

Primary

MeasureTime frame
organ-preservation rate;

Secondary

MeasureTime frame
overall survival;

Countries

China

Contacts

Public ContactZhao Dan

Beijing Cancer Hospital

danzhao@bjcancer.org.cn+86 188 1318 5350

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026